(Q34750119)

4 August 2017

1 reference

title

Newer long-term treatments for multiple sclerosis (English)

1 reference

4 August 2017

0 references

William Pryse-Phillips

series ordinal

1

1 reference

4 August 2017

publication date

1 July 2002

1 reference

Clinical Neurology and Neurosurgery

4 August 2017

published in

1 reference

4 August 2017

volume

104

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

265-271

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

1 reference

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Recombinant interferon-beta-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Overview of azathioprine treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Why treat early multiple sclerosis patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Multiple sclerosis-from probable to definite diagnosis: a 7-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Drug treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Guidelines for physicians with patients on IFN beta-1b: the use of an assay for neutralizing antibodies (NAB)

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0303-8467%2802%2900050-1

7 January 2021

10.1016/S0303-8467(02)00050-1

Identifiers

DOI

1 reference

4 August 2017

1 reference